REVIEW article
Front. Endocrinol.
Sec. Diabetes: Molecular Mechanisms
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1663728
This article is part of the Research TopicInflammatory biomarkers in Type 1 diabetesView all 3 articles
Single-cell RNA sequencing (scRNA-seq) in studies of type 1 diabetes mellitus (T1D): modern state-of-the-art and technical peculiarities
Provisionally accepted- 1Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal medical and biological agency, Moscow, Russia
- 2Institute of Basic Biological Problems RAS - a separate subdivision of Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Pushchino, Russia
- 3Institute of Cell Biophysics - a separate subdivision of the Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Pushchino, Russia
- 4Federal State Budgetary Scientific Institution "Federal Research Center for innovator and emerging biomedical and pharmaceutical technologies", Moscow, Russia
- 5Moscow Center for Advanced Studies, Moscow, Russia
- 6GBUZ Moskovskij Kliniceskij Naucno-prakticeskij Centr imeni A S Loginova Departamenta zdravoohranenia goroda Moskvy, Moscow, Russia
- 7Moskovskij gosudarstvennyj universitet imeni M V Lomonosova, Moscow, Russia
- 8Federal'noe mediko-biologiceskoe agentstvo Rossii, Moscow, Russia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Type 1 diabetes mellitus (T1DM) is an autoimmune disease leading to destruction of pancreatic β-cells and loss of insulin production ability. Pathogenesis of T1DM is a complex process involving different types of immune cells, particularly, T-lymphocytes (including effector cells, Thelpers, regulatory lymphocytes, MAIT cells), B-lymphocytes, natural killers, monocytes, dendritic cells, and other minor cellular populations that form autoimmune response against islet cells.The heterogeneity of intercellular communications in the pancreas and adjacent lymph nodes of patients, as well as diverse functional state of islet cells, make a significant contribution to the pathogenesis of this disease. This makes the detailed consideration of immune cell 1 Abdullatypov et al.subpopulations very essential for investigating the pathogenesis of the disease. Understanding the relations between changes of transcriptional activities in different cellular subtypes may allow to study the pathogenetic mechanism of T1DM in more detail, which could further be applied in both diagnostics and treatment. Single-cell RNA sequencing (scRNA-seq) allows to examine the interactions between immune cell subtypes and to identify differentially expressed genes specific for early stages of T1DM in particular cell subtypes. This review summarizes modern studies focusing on application of scRNA-seq for the studies of T1DM pathogenesis, novel biomarkers of manifestation, progression, and treatment efficiency for diabetes and its complications. The review covers studies on different cells and human tissues (endocrine, exocrine and immune pancreatic cells, PBMC) and model animals with experimental T1DM and its complications.
Keywords: type 1 diabetes mellitus, ScRNA-seq, complete transcriptome analysis, cDNA libraries, Third-generation sequencing
Received: 10 Jul 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Abdullatypov, Glushkova, Petriaikina, Bogdanov, Antysheva, Tabakov, Akimov, Yudin, Keskinov, Yudin, Volchkov, Svetlichnyy, Woroncow and Skvortsova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Azat Vadimovich Abdullatypov, Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal medical and biological agency, Moscow, Russia
Dmitry Vladimirovich Svetlichnyy, Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal medical and biological agency, Moscow, Russia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.